Protease inhibitor and triple-drug therapy
- 1 December 1998
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (18) , 2397-2406
- https://doi.org/10.1097/00002030-199818000-00008
Abstract
To assess whether treatment of HIV-positive children by antiretroviral drugs for a 6-month period would improve immune function significantly. Immunological assessment of 89 HIV-positive children who received protease inhibitor monotherapy for 12–16 weeks as part of phase I/II studies, followed by triple antiretroviral therapy for an additional 12 weeks, was conducted. Immunological parameters were assessed in vitro at four time points (at enrollment, at weeks 2–4, at weeks 12–16, and at weeks 24–28). Assessments included: cytokine production by monocytes, T-cell proliferation to mitogen or recall antigens (including an HIV antigen) and apoptotic cell death. Plasma levels of tumor necrosis factor (TNF)-α and soluble TNF receptor (sTNF-R) were also measured, in addition to CD4+ T-lymphocyte counts and viral load. In addition, limited analyses were performed on samples from 17 children after 120 weeks of therapy, including 104 weeks of triple therapy. At enrollment, the 89 children exhibited severe immune defects. Antiretroviral therapy raised CD4+ T-lymphocyte counts significantly and decreased viral loads. In contrast, the in vitro immune parameters studied were not improved, except for plasma levels of sTNF-RII which decreased in parallel with the decrease in viral load. In addition, there was a trend towards increased skin test reactivity for the ritonavir-treated children. No differences were seen in the immune parameters whether the patients were treated with mono- or triple therapy. Results obtained after 120 weeks of therapy demonstrated that defective interleukin-12 production was not restored by long-term therapy. After 6 months of therapy, with the exception of decreased sTNF-RII levels, and a trend towards increased skin test reactivity, restoration of several defective cellular immune responses did not occur despite significantly decreased viral loads and increased CD4+ T-lymphocyte counts.Keywords
This publication has 27 references indexed in Scilit:
- A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV InfectionPublished by American Academy of Pediatrics (AAP) ,1998
- A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus InfectionPediatrics, 1998
- Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcomeAIDS, 1996
- Delayed–type hypersensitivity skin testing in human immunodeficiency virus–infected pediatric patientsThe Journal of Pediatrics, 1996
- Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infectionInfection, 1996
- Molecular Analysis of Decreased Interleukin-12 Production in Persons Infected with Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1996
- Human Immunodeficiency Virus Infection in the US Air Force: Seroconversions, Clinical Staging, and Assessment of a T Helper Cell Functional Assay to Predict Change in CD4+ T Cell CountsThe Journal of Infectious Diseases, 1991
- Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.Journal of Clinical Investigation, 1989
- Delayed-type hypersensitivity skin testing. A reviewArchives of Dermatology, 1983
- Plots of P-values to evaluate many tests simultaneouslyBiometrika, 1982